Pharmaceutical giant Novartis is strategically positioning itself to overcome significant patent expirations, even as its highly anticipated multiple sclerosis (MS) drug, remibrutinib, faces scrutiny over its market potential. The company recently reported improved third-quarter profitability, signaling a successful transition beyond the steepest patent cliff in its history. However, the outlook for remibrutinib, championed by CEO […]